Lippincott ^® NursingCenter ^®

Departments

• Free

  3 Questions on...The Problem With Clinical Trial Enrollment: With PAUL SABBATINI, MD, Deputy Physician-in-Chief for Clinical Research at Memorial Sloan Kettering Cancer Center

  Sarah DiGiulio

• Free

  ABVD, BEACOPP Show Similar Survival But Different Toxicities

  Robert H. Carlson

• Free

  Atezolizumab Shows First-line Activity in Advanced Bladder Cancer

  Mark L. Fuerst

• Free

  Dabrafenib Plus Trametinib Combination Treats Rare Lung Cancer

  Mark L. Fuerst

• Free

  Dabrafenib Plus Trametinib Improves Survival in Advanced Melanoma

  Mark L. Fuerst

• Free

  Early Palliative Care Improves Outcomes for Family Caregivers

  Mark L. Fuerst

• Free

  Extended AI Therapy in Postmenopausal Women With Early Breast Cancer

  Romi Herron-Cologna

• Free

  Fast-Track Designation for a Treatment for Ewing Sarcoma
• Free

  First Blood Test to Detect Gene Mutation Associated with NSCLC
• Free

  From the Trenches: A ‘SWOT’ Analysis of the Practice of Clinical Oncology

  Joseph V. Simone MD

• Free

  Liquid Biopsy May Aid Treatment Decisions in Solid Tumors

  Mark L. Fuerst

• Free

  Liquid Biopsy: ‘Method of the Future’ For Lung Cancer Prediction

  Peter M. Goodwin

• Free

  Ongoing Study Assesses Effectiveness of BBI-608

  Catlin Nalley

• Free

  Online Research Program Enrolls Patients With Breast Cancer
• Free

  Patient Handout: Talking With Your Children

  Wendy Harpham MD, FACP

• Free

  Precision Medicine to Expand Cancer Therapies
• Free

  Pre-Treated T790M-Positive Lung Cancer: Osimertinib Benefit Confirmed

  Peter M. Goodwin

• Free

  Primary Tumor Locations Predicts Survival in Colorectal Cancer

  Mark L. Fuerst

• Free

  Racial Disparity in Breast & Ovarian Cancer Risk Management
• Free

  Shop Talk
• Free

  Who Leads End-of-Life Discussions Matters, Study Reports

  Catlin Nalley

• Buy

  Chemoradiation & Temozolomide for Patients With Glioblastoma

  Romi Herron-Cologna

• Buy

  Is MRD Negativity Necessary for CLL Patients?

  Mark L. Fuerst

• Buy

  Patient-Driven Model May Accelerate Breast Cancer Research

  Mark L. Fuerst

• Buy

  Patients With Advanced Cancer Choose Aggressive Care Near End of Life